Home » Stocks » DXCM

DexCom, Inc. (DXCM)

Stock Price: $459.92 USD 11.34 (2.53%)
Updated Jul 28, 2021 4:00 PM EDT - Market closed
Pre-market: $452.00 -7.92 (-1.72%) Jul 29, 4:27 AM
Market Cap 43.38B
Revenue (ttm) 2.03B
Net Income (ttm) 514.00M
Shares Out 96.30M
EPS (ttm) 5.21
PE Ratio 88.36
Forward PE 200.00
Dividend n/a
Dividend Yield n/a
Trading Day July 28
Last Price $459.92
Previous Close $448.58
Change ($) 11.34
Change (%) 2.53%
Day's Open 448.56
Day's Range 447.60 - 461.00
Day's Volume 374,328
52-Week Range 305.63 - 463.22

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

AEVA, BKD, CSGS, DXCM and EIG have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2021.

Other stocks mentioned: AEVA, BKD, CSGS, EIG
18 hours ago - Zacks Investment Research

DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.

5 days ago - Zacks Investment Research

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 days ago - Zacks Investment Research

Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.

1 week ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #API--FDA Clears Dexcom Real-Time APIs for Third-Party Apps and Devices

1 week ago - Business Wire

ONEM, BABA, DXCM, ORAN, and MTH have been added to the Zacks Rank #5 (Strong Sell) List on July 13, 2021

Other stocks mentioned: BABA, MTH, ONEM, ORAN
2 weeks ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)-- #dxcm--Dexcom Schedules Second Quarter 2021 Earnings Release and Conference Call for July 29, 2021 at 4:30 p.m. Eastern Time

3 weeks ago - Business Wire

DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021

Other stocks mentioned: GP, MAXR, PHR, RAD
3 weeks ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)-- #ADA--Dexcom CGM Plays Starring Role at 81st Scientific Sessions of the American Diabetes Association

1 month ago - Business Wire

CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.

Other stocks mentioned: ABT, MDT, TNDM
1 month ago - Zacks Investment Research

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #DXCM--DexCom, Nick Jonas and Leading Diabetes Nonprofits Launch Initiative to Help Improve the Lives of People With Diabetes

1 month ago - Business Wire

Last month, we discussed why the sell-off in Dexcom Stock (NASDAQ: DXCM) was unwarranted, and we expected it to see higher levels. Since then, DXCM stock has rallied 18%, while it is up 23% over the las...

1 month ago - Forbes

Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.

1 month ago - Zacks Investment Research

Despite recent struggles, the investment thesis for this company remains strong.

Other stocks mentioned: ABT
1 month ago - The Motley Fool

BURNABY, British Columbia--(BUSINESS WIRE)---- $DXCM #cgm--Dexcom announces that people with diabetes may now be eligible for provincial coverage of the Dexcom G6 CGM System through BC PharmaCare.

1 month ago - Business Wire

SAN DIEGO--(BUSINESS WIRE)---- $DXCM #CGM--Dexcom Looks to the Future of Continuous Glucose Monitoring

1 month ago - Business Wire

Analysts have provided the following ratings for DexCom (NASDAQ:DXCM) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2 0 0 Somewhat Bullish 0 2 1 0 Indifferent 1 0...

2 months ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Conference Presentation

2 months ago - Business Wire

The best is yet to come for these winning growth stocks.

Other stocks mentioned: NFLX
2 months ago - The Motley Fool

No news was good news for the healthcare stock.

2 months ago - The Motley Fool

These three healthcare stocks have proven that growth and long-term trends are on their side.

Other stocks mentioned: CVS, MEDP
2 months ago - The Motley Fool

For these two companies, the bull case remains intact.

Other stocks mentioned: NFLX
2 months ago - The Motley Fool

While there have been rumors of AppleAAPL coming up with a CGM feature in its Apple Watch, the company hasn't confirmed it yet. That said, if Apple does come up with this feature, it will surely take ...

2 months ago - Forbes

Investors were not pleased with the company's latest earnings report.

2 months ago - The Motley Fool

DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

2 months ago - Zacks Investment Research

DexCom (DXCM) delivered earnings and revenue surprises of 6.45% and 4.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of DexCom (NASDAQ:DXCM) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 25.00% over the past year to $0.33, which beat the estim...

2 months ago - Benzinga

SAN DIEGO--(BUSINESS WIRE)--Dexcom Reports First Quarter 2021 Financial Results

2 months ago - Business Wire

DexCom (DXCM) has moved higher as of late, but there could definitely be trouble on the horizon for this company

3 months ago - Zacks Investment Research

Up over 250% in less than a year, what's behind the rise of this hot stock?

Other stocks mentioned: ABT, MDT, SENS
3 months ago - The Motley Fool

Steer clear of toxic stocks like MELI, HQY, DXCM, STNE and LVS to safeguard your portfolio.

Other stocks mentioned: HQY, LVS, MELI, STNE
3 months ago - Zacks Investment Research

DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.

3 months ago - Zacks Investment Research

DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

Each proved its worth during the coronavirus pandemic.

Other stocks mentioned: ADBE, FDX
3 months ago - The Motley Fool

EDINBURGH, Scotland--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today it has ended its distributi...

3 months ago - Business Wire

Will future Tyvaso revenue growth push United Therapeutics to new heights?

Other stocks mentioned: UTHR
3 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules First Quarter 2021 Earnings Release and Conference Call for April 29, 2021 at 4:30 p.m. Eastern Time.

3 months ago - Business Wire

Financial media can often divert your attention away from the best investments.

Other stocks mentioned: ALGN, RGEN
3 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)---- $DXCM--Dexcom Promotes Jereme Sylvain to Chief Financial Officer

4 months ago - Business Wire

Tandem Diabetes (TNDM) is expects t:sport to be a major growth catalyst for 2022.

Other stocks mentioned: ABT
4 months ago - Zacks Investment Research

Toxic stocks are vulnerable to external shocks and are burdened with huge debts. It's important to ensure that you safeguard your portfolio from such stocks.

Other stocks mentioned: CDAY, CWST, HXL
4 months ago - Zacks Investment Research

When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can hel...

Other stocks mentioned: BDX, MDT
4 months ago - 24/7 Wall Street

Lone Pine Capital, the hedge fund founded by Steve Mandel (Trades, Portfolio) in 1997, disclosed its fourth-quarter 2020 portfolio last week.

Other stocks mentioned: BILI, COF, CVNA, FB, PYPL, SNAP
5 months ago - GuruFocus

Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.

Other stocks mentioned: HXL, PAYC, RCM
5 months ago - Zacks Investment Research

DexCom Inc. (NASDAQ:DXCM) said it expects 2021 revenue to increase between 15% and 20% to more than $2.2 billion as it extends its diabetes care business into two new areas of the disease, prediabetes a...

5 months ago - GuruFocus

If the market plunges, picking up these fast-paced companies at a discount would be a wise move.

Other stocks mentioned: AMZN, CRWD, IIPR
5 months ago - The Motley Fool

SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations

5 months ago - Business Wire

DexCom CEO says Super Bowl ad sparked high interest in its glucose tracker

YouTube video

DexCom CEO Kevin Sayer said the company had 5 times more media impressions in one day than it had all last year after airing Super Bowl spot featuring Nick Jonas, helping to get the message out about it...

5 months ago - CNBC Television

DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

5 months ago - Zacks Investment Research

DexCom (DXCM) delivered earnings and revenue surprises of 0.00% and 1.88%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

About DXCM

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LL... [Read more...]

Industry
Diagnostics & Research
IPO Date
Apr 14, 2005
CEO
Kevin Sayer
Employees
5,500
Stock Exchange
NASDAQ
Ticker Symbol
DXCM
Full Company Profile

Financial Performance

In 2020, DexCom's revenue was $1.93 billion, an increase of 30.54% compared to the previous year's $1.48 billion. Earnings were $493.60 million, an increase of 388.23%.

Financial Statements

Analyst Forecasts

According to 21 analysts, the average rating for DexCom stock is "Buy." The 12-month stock price forecast is 477.95, which is an increase of 3.92% from the latest price.

Price Target
$477.95
(3.92% upside)
Analyst Consensus: Buy